23455-78-9

Basic information

• Product Name: 5-(4-aminophenyl)-1,2-dihydro-3H-1,2,4-triazole-3-thione
• CAS NO: 23455-78-9
• Molecular Formula: C₈H₈N₄S
• Molecular Weight: 192.2409
• Mol File: 23455-78-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 340.5°C at 760 mmHg
• Flash Point: 159.7°C
• Density: 1.55g/cm³
• Vapor Pressure: 8.58E-05mmHg at 25°C
• Refractive Index: 1.794
• CAS DataBase Reference: 5-(4-aminophenyl)-1,2-dihydro-3H-1,2,4-triazole-3-thione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-aminophenyl)-1,2-dihydro-3H-1,2,4-triazole-3-thione(23455-78-9)
• EPA Substance Registry System: 5-(4-aminophenyl)-1,2-dihydro-3H-1,2,4-triazole-3-thione(23455-78-9)

Safety Data

• Hazardous Substances Data: 23455-78-9(Hazardous Substances Data)

Upstream product

• 49716-11-2 acetic acid-[4-(5-thioxo-2,5-dihydro-1H-[1,2,4]triazol-3-yl)-anilide] 
• 412312-87-9 acetic acid-[4-(5-benzylmercapto-1H-[1,2,4]triazol-3-yl)-anilide] 
• 836-16-8 1-(4-nitrobenzoyl)thiosemicarbazide 
• 6898-56-2 5-(4-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 
• 62-23-7 4-nitro-benzoic acid 
• 122-04-3 4-nitro-benzoyl chloride 
• 619-45-4 4-methoxycarbonyl aniline 
• 5351-17-7 4-aminobenzohydrazide 
• 85106-57-6 C₈H₈N₃OS₂^(1-)*K⁽¹⁺⁾ 

Relevant articles and documents

Synthesis and biological evaluation of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione as antimycobacterial agents

Resistance among dormant mycobacteria leading to multidrug-resistant and extremely drug-resistant tuberculosis is one of the major threats. Hence, a series of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione derivatives (4a–5c) have been synthesized and screened for their antitubercular activity against Mycobacterium tuberculosis H37Ra (H37Ra). The triazolethiones 4b and 4v showed high antitubercular activity (both MIC and IC50) against the dormant H37Ra by in vitro and ex vivo. They were shown to have more specificity toward mycobacteria than other Gram-negative and Gram-positive pathogenic bacteria. The cytotoxicity was almost insignificant up to 100?μg/ml against THP-1, A549, and PANC-1 human cancer cell lines, and solubility was high in aqueous solution, indicating the potential of developing these compounds further as novel therapeutics against tuberculosis infection.

Synthesis and invitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold

In recent years, clinical symptoms resulting from West Nile virus (WNV) infection have worsened in severity, with an increased frequency in neuroinvasive diseases among the elderly. As there are presently no successful therapies against WNV for use in humans, continual efforts to develop new chemotherapeutics against this virus are highly desired. The viral NS2B-NS3 protease is a promising target for viral inhibition due to its importance in viral replication and its unique substrate preference. In this study, a WNV NS2B-NS3 protease inhibitor with a 2-{6-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold was identified during screening. Optimization of this initial hit by synthesis and screening of a focused compound library with this scaffold led to the identification of a novel uncompetitive inhibitor (1a24, IC50=3.4±0.2μM) of the WNV NS2B-NS3 protease. Molecular docking of 1a24 into the WNV protease showed that the compound interferes with productive interactions of the NS2B cofactor with the NS3 protease and is an allosteric inhibitor of the WNV NS3 protease.